Alphatec Spine reported $47.6 million in third quarter revenue, a 6.2 percent increase over the same period last year, according to an Alphatec Spine news release.
While international revenue only grew by 0.7 percent, the company reported 8.9 percent growth in the U.S. markets to $32.7 million. During the third quarter, the company re-launched Alphatec Solus to global beta sites and recently introduced three new products at the North American Spine Society meeting in Chicago.
The company's President and CEO Dirk Kuyper attributed its success to a broad product portfolio and focus on laser technology in the aging spine, minimally invasive surgery and biologics markets.
Related Articles on Spine Devices:
RTI Biologics Announces 3Q Worldwide Revenues of $42.3M, Up 1%
Mazor Robotics Announces 15k Implants Using Robotic Spine Surgery Technology
LDR Receives FDA Clearance for Oblique ALIF Cage
The company's President and CEO Dirk Kuyper attributed its success to a broad product portfolio and focus on laser technology in the aging spine, minimally invasive surgery and biologics markets.
Related Articles on Spine Devices:
RTI Biologics Announces 3Q Worldwide Revenues of $42.3M, Up 1%
Mazor Robotics Announces 15k Implants Using Robotic Spine Surgery Technology
LDR Receives FDA Clearance for Oblique ALIF Cage